Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q3 EPS of ($0.25), versus $0.96 reported last year. Revenue for the quarter came in at $4.35 million, versus $72.28 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel names former board member as chief medical officer
- Nike (NKE) Tops Q4 EPS by 8c
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
